Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Effect of abuse-deterrent formulation of OxyContin.

Cicero TJ, Ellis MS, Surratt HL.

N Engl J Med. 2012 Jul 12;367(2):187-9. doi: 10.1056/NEJMc1204141. No abstract available.

2.

Characteristics of opioid prescriptions in 2009.

Volkow ND, McLellan TA, Cotto JH, Karithanom M, Weiss SR.

JAMA. 2011 Apr 6;305(13):1299-301. doi: 10.1001/jama.2011.401. No abstract available.

3.
4.

Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?

Schneider JP, Matthews M, Jamison RN.

CNS Drugs. 2010 Oct;24(10):805-10. doi: 10.2165/11584260-000000000-00000. Review.

PMID:
20839893
5.

Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.

Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL.

Psychopharmacology (Berl). 2010 Oct;212(2):193-203. doi: 10.1007/s00213-010-1942-4. Epub 2010 Jul 28.

6.

Determinants of fentanyl and other potent ยต opioid agonist misuse in opioid-dependent individuals.

Cicero TJ, Ellis MS, Paradis A, Ortbal Z.

Pharmacoepidemiol Drug Saf. 2010 Oct;19(10):1057-63. doi: 10.1002/pds.1989.

7.

Tramadol acts as a weak reinforcer in the rat self-administration model, consistent with its low abuse liability in humans.

O'Connor EC, Mead AN.

Pharmacol Biochem Behav. 2010 Sep;96(3):279-86. doi: 10.1016/j.pbb.2010.05.018. Epub 2010 May 24.

PMID:
20580909
8.

Emergency department visits involving nonmedical use of selected prescription drugs - United States, 2004-2008.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Jun 18;59(23):705-9.

10.

Abuse liability of oxycodone as a function of pain and drug use history.

Comer SD, Sullivan MA, Vosburg SK, Kowalczyk WJ, Houser J.

Drug Alcohol Depend. 2010 Jun 1;109(1-3):130-8. doi: 10.1016/j.drugalcdep.2009.12.018. Epub 2010 Jan 15.

11.

Measuring attractiveness for abuse of prescription opioids.

Butler SF, Fernandez KC, Chang A, Benoit C, Morey LC, Black R, Katz N.

Pain Med. 2010 Jan;11(1):67-80. doi: 10.1111/j.1526-4637.2009.00736.x. Epub 2009 Nov 25.

12.

Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.

Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E.

Clin Drug Investig. 2009;29(12):777-90. doi: 10.2165/11530800-000000000-00000. Erratum in: Clin Drug Investig. 2011;31(8):598.

PMID:
19888784
13.

The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.

Mammen K, Bell J.

Expert Opin Pharmacother. 2009 Oct;10(15):2537-44. doi: 10.1517/14656560903213405. Review.

PMID:
19708849
14.

Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.

Webster L.

Pain Med. 2009 Jul;10 Suppl 2:S124-33. doi: 10.1111/j.1526-4637.2009.00672.x. Review.

15.

Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: a randomized cross-over trial.

Wilsey BL, Fishman S, Li CS, Storment J, Albanese A.

Pharmacol Biochem Behav. 2009 Nov;94(1):98-107. doi: 10.1016/j.pbb.2009.07.014. Epub 2009 Aug 4.

16.

Can abuse deterrent formulations make a difference? Expectation and speculation.

Budman SH, Grimes Serrano JM, Butler SF.

Harm Reduct J. 2009 May 29;6:8. doi: 10.1186/1477-7517-6-8.

17.

Co-morbidity and utilization of medical services by pain patients receiving opioid medications: data from an insurance claims database.

Cicero TJ, Wong G, Tian Y, Lynskey M, Todorov A, Isenberg K.

Pain. 2009 Jul;144(1-2):20-7. doi: 10.1016/j.pain.2009.01.026. Epub 2009 Apr 10.

18.

National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.

Butler SF, Budman SH, Licari A, Cassidy TA, Lioy K, Dickinson J, Brownstein JS, Benneyan JC, Green TC, Katz N.

Pharmacoepidemiol Drug Saf. 2008 Dec;17(12):1142-54. doi: 10.1002/pds.1659.

PMID:
18932173
19.

The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.

Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr.

Drug Alcohol Depend. 2008 Dec 1;98(3):191-202. doi: 10.1016/j.drugalcdep.2008.05.007. Epub 2008 Jul 7.

20.

Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R).

Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN.

J Pain. 2008 Apr;9(4):360-72. doi: 10.1016/j.jpain.2007.11.014. Epub 2008 Jan 22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk